WO2015053871A3 - NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa - Google Patents

NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa Download PDF

Info

Publication number
WO2015053871A3
WO2015053871A3 PCT/US2014/052631 US2014052631W WO2015053871A3 WO 2015053871 A3 WO2015053871 A3 WO 2015053871A3 US 2014052631 W US2014052631 W US 2014052631W WO 2015053871 A3 WO2015053871 A3 WO 2015053871A3
Authority
WO
WIPO (PCT)
Prior art keywords
functional fragment
antibody
sialyl
lewisa
nucleic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/052631
Other languages
French (fr)
Other versions
WO2015053871A2 (en
WO2015053871A4 (en
WO2015053871A8 (en
Inventor
Ritsuko Sawada
Shu-Man Sun
Wolfgang Scholz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MabVax Therapeutics Inc
Original Assignee
MabVax Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to LTEPPCT/US2014/052631T priority Critical patent/LT3041507T/en
Priority to CN202011316903.2A priority patent/CN112695039B/en
Priority to EP21181759.8A priority patent/EP3906945A3/en
Priority to JP2016539019A priority patent/JP6626445B2/en
Priority to NZ717428A priority patent/NZ717428B2/en
Priority to KR1020227004406A priority patent/KR102553717B1/en
Priority to CN201480057851.8A priority patent/CN105764526B/en
Priority to BR112016004133-0A priority patent/BR112016004133B1/en
Priority to KR1020217019368A priority patent/KR102362630B1/en
Priority to RS20210929A priority patent/RS62189B1/en
Priority to AU2014332442A priority patent/AU2014332442B2/en
Priority to DK14852746.8T priority patent/DK3041507T3/en
Priority to RU2016111015A priority patent/RU2699289C2/en
Priority to KR1020207019821A priority patent/KR102313341B1/en
Priority to KR1020167007644A priority patent/KR20160054501A/en
Priority to EP14852746.8A priority patent/EP3041507B1/en
Priority to ES14852746T priority patent/ES2880709T3/en
Priority to SM20210427T priority patent/SMT202100427T1/en
Application filed by MabVax Therapeutics Inc filed Critical MabVax Therapeutics Inc
Priority to PL14852746T priority patent/PL3041507T3/en
Priority to CA2922478A priority patent/CA2922478C/en
Priority to SI201431854T priority patent/SI3041507T1/en
Priority to HRP20211129TT priority patent/HRP20211129T1/en
Publication of WO2015053871A2 publication Critical patent/WO2015053871A2/en
Publication of WO2015053871A3 publication Critical patent/WO2015053871A3/en
Publication of WO2015053871A4 publication Critical patent/WO2015053871A4/en
Priority to IL244297A priority patent/IL244297B/en
Anticipated expiration legal-status Critical
Priority to ZA2016/01354A priority patent/ZA201601354B/en
Publication of WO2015053871A8 publication Critical patent/WO2015053871A8/en
Priority to AU2020201225A priority patent/AU2020201225B2/en
Priority to IL276819A priority patent/IL276819A/en
Priority to CY20211100653T priority patent/CY1124435T1/en
Priority to AU2022209226A priority patent/AU2022209226B2/en
Priority to AU2025223771A priority patent/AU2025223771A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Sialyl-Lewisa (sLea). The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to sLea. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.
PCT/US2014/052631 2013-08-26 2014-08-26 NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa Ceased WO2015053871A2 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
CN202011316903.2A CN112695039B (en) 2013-08-26 2014-08-26 Nucleic acid encoding human antibodies against sialyl lewis a antigen
EP21181759.8A EP3906945A3 (en) 2013-08-26 2014-08-26 Nucleic acids encoding human antibodies to sialyl-lewis a
JP2016539019A JP6626445B2 (en) 2013-08-26 2014-08-26 Nucleic acids encoding human antibodies to sialyl-Lewis a
NZ717428A NZ717428B2 (en) 2013-08-26 2014-08-26 NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
KR1020227004406A KR102553717B1 (en) 2013-08-26 2014-08-26 Nucleic acids encoding human antibodies to sialyl-lewis a
CN201480057851.8A CN105764526B (en) 2013-08-26 2014-08-26 Nucleic acid encoding human antibody against sialylated Lewis a antigen
BR112016004133-0A BR112016004133B1 (en) 2013-08-26 2014-08-26 ISOLATED POLYNUCLEOTIDES, ISOLATED ANTIBODY OR FUNCTIONAL FRAGMENT THEREOF THAT BINDS TO SIALILLEWISA, USES THEREOF, CONJUGATE AND PHARMACEUTICAL COMPOSITION
KR1020217019368A KR102362630B1 (en) 2013-08-26 2014-08-26 Nucleic acids encoding human antibodies to sialyl-lewis a
RS20210929A RS62189B1 (en) 2013-08-26 2014-08-26 Nucleic acids encoding human antibodies to sialyl-lewis a
AU2014332442A AU2014332442B2 (en) 2013-08-26 2014-08-26 Nucleic acids encoding human antibodies to Sialyl-Lewis
DK14852746.8T DK3041507T3 (en) 2013-08-26 2014-08-26 NUCLEIC ACIDS ENCOODING HUMAN ANTIBODIES TO SIALYL-LEWIS A
RU2016111015A RU2699289C2 (en) 2013-08-26 2014-08-26 Nucleic acids encoding human antibodies to sialyl-lewisa
KR1020207019821A KR102313341B1 (en) 2013-08-26 2014-08-26 Nucleic acids encoding human antibodies to sialyl-lewis a
KR1020167007644A KR20160054501A (en) 2013-08-26 2014-08-26 Nucleic acids encoding human antibodies to sialyl-lewis a
EP14852746.8A EP3041507B1 (en) 2013-08-26 2014-08-26 Nucleic acids encoding human antibodies to sialyl-lewis a
SM20210427T SMT202100427T1 (en) 2013-08-26 2014-08-26 Nucleic acids encoding human antibodies to sialyl-lewis a
ES14852746T ES2880709T3 (en) 2013-08-26 2014-08-26 Nucleic acids encoding human antibodies against Sialyl-Lewis A
LTEPPCT/US2014/052631T LT3041507T (en) 2013-08-26 2014-08-26 NUCLEAR ACIDS CODING ANTIBODIES TO SIALIL-LEWIS A
PL14852746T PL3041507T3 (en) 2013-08-26 2014-08-26 NUCLEIC ACIDS CODE HUMAN ANTIBODIES AGAINST SALYL-LEWIS A
CA2922478A CA2922478C (en) 2013-08-26 2014-08-26 Nucleic acids encoding human antibodies to sialyl-lewisa
SI201431854T SI3041507T1 (en) 2013-08-26 2014-08-26 Nucleic acids encoding human antibodies to sialyl-lewis a
HRP20211129TT HRP20211129T1 (en) 2013-08-26 2014-08-26 Nucleic acids encoding human antibodies to sialyl-lewis a
IL244297A IL244297B (en) 2013-08-26 2016-02-25 Amino acids encoding human antibodies to sialyl-lewisa
ZA2016/01354A ZA201601354B (en) 2013-08-26 2016-02-26 Nucleic acids encoding human antibodies to sialyl-lewisa
AU2020201225A AU2020201225B2 (en) 2013-08-26 2020-02-20 Nucleic acids encoding human antibodies to Sialyl-Lewisa
IL276819A IL276819A (en) 2013-08-26 2020-08-19 Nucleic acids encoding human antibodies to sialyl-lewisa
CY20211100653T CY1124435T1 (en) 2013-08-26 2021-07-21 NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A
AU2022209226A AU2022209226B2 (en) 2013-08-26 2022-07-26 Nucleic acids encoding human antibodies to Sialyl-Lewisa
AU2025223771A AU2025223771A1 (en) 2013-08-26 2025-08-27 Nucleic acids encoding human antibodies to Sialyl-Lewisa

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361870137P 2013-08-26 2013-08-26
US61/870,137 2013-08-26

Publications (4)

Publication Number Publication Date
WO2015053871A2 WO2015053871A2 (en) 2015-04-16
WO2015053871A3 true WO2015053871A3 (en) 2015-06-11
WO2015053871A4 WO2015053871A4 (en) 2015-07-30
WO2015053871A8 WO2015053871A8 (en) 2016-03-31

Family

ID=52480556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/052631 Ceased WO2015053871A2 (en) 2013-08-26 2014-08-26 NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa

Country Status (22)

Country Link
US (4) US9475874B2 (en)
EP (2) EP3906945A3 (en)
JP (7) JP6626445B2 (en)
KR (4) KR102553717B1 (en)
CN (2) CN105764526B (en)
AU (4) AU2014332442B2 (en)
CA (2) CA3090644C (en)
CY (1) CY1124435T1 (en)
DK (1) DK3041507T3 (en)
ES (1) ES2880709T3 (en)
HR (1) HRP20211129T1 (en)
HU (1) HUE056325T2 (en)
IL (2) IL244297B (en)
LT (1) LT3041507T (en)
PL (1) PL3041507T3 (en)
PT (1) PT3041507T (en)
RS (1) RS62189B1 (en)
RU (1) RU2699289C2 (en)
SI (1) SI3041507T1 (en)
SM (1) SMT202100427T1 (en)
WO (1) WO2015053871A2 (en)
ZA (1) ZA201601354B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137695B (en) * 2015-08-25 2022-03-29 斯坎塞尔有限公司 Sialylated diluisia a expressed on glycoproteins other than glycolipids as a functional cancer target and antibodies thereto

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015053871A2 (en) * 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
ES3054991T3 (en) * 2015-10-30 2026-02-09 Medimmune Ltd Prevention of n-terminal truncation in igg light chains
CA3028035A1 (en) * 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
MY195529A (en) 2016-11-18 2023-01-30 Astellas Pharma Inc Novel Anti-Human MUC1 Antibody Fab Fragment
IL324632A (en) 2016-12-01 2026-01-01 Regeneron Pharma Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
CN110650974B (en) 2017-02-10 2024-04-19 瑞泽恩制药公司 Radiolabeled anti-LAG 3 antibodies for immune-PET imaging
WO2018232349A1 (en) * 2017-06-15 2018-12-20 Development Center For Biotechnology Antibody-drug conjugates containing anti-globo h antibodies and uses thereof
TWI795415B (en) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 A novel anti-human CEACAM5 antibody Fab fragment
MY197688A (en) 2017-07-24 2023-07-05 Regeneron Pharma Anti-cd8 antibodies and uses thereof
PE20201339A1 (en) * 2017-12-19 2020-11-25 Univ Rockefeller HUMAN IGG HR DOMAIN VARIANTS WITH IMPROVED EFFECTIVE FUNCTION
PT110526B (en) 2018-01-26 2021-02-04 Univ Nova De Lisboa ANTIBODY, FUNCTIONAL FRAGMENT OR PROBE OF THE SAME AGAINST TUMORAL ANTIGENS
KR102115236B1 (en) * 2018-01-29 2020-05-27 (주)에스엠티바이오 Chimera antigen receptors for treating pancreatic cancer or biliary tract cancer
WO2019221269A1 (en) 2018-05-17 2019-11-21 アステラス製薬株式会社 COMPLEX HAVING ANTI-HUMAN MUC1 ANTIBODY Fab FRAGMENT, PEPTIDE LINKER AND/OR LIGAND
EP3849605A4 (en) * 2018-09-10 2022-06-15 Cold Spring Harbor Laboratory METHODS OF TREATMENT OF PANCREATITIS
MY205764A (en) 2018-10-10 2024-11-12 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
WO2020081988A1 (en) * 2018-10-19 2020-04-23 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptor targeting sialyl lewis a and uses thereof
JP7750828B2 (en) 2019-09-16 2025-10-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Radiolabeled MET-binding proteins for immunoPET imaging
US12552874B2 (en) 2019-11-26 2026-02-17 Ramot At Tel-Aviv University Ltd. Antibodies to carbohydrate antigens
CN114605550B (en) * 2020-12-08 2023-09-22 东莞市朋志生物科技有限公司 Antibodies against CA19-9, applications thereof and kits for detecting CA19-9
US20250297027A1 (en) * 2021-01-12 2025-09-25 Yeda Research And Development Co. Ltd. Antibodies to cancer glycosylation and uses thereof
EP4314077A1 (en) 2021-03-26 2024-02-07 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
WO2025038668A1 (en) 2023-08-14 2025-02-20 Voro Therapeutics, Inc. Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
WO2025261951A1 (en) 2024-06-18 2025-12-26 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039027A2 (en) * 1997-03-05 1998-09-11 John Wayne Cancer Institute Sialyl lewis antigens as targets for immunotherapy
US20050003469A1 (en) * 1998-12-02 2005-01-06 Applied Molecular Evolution, Inc. Tumor specific human monoclonal antibodies and methods of use
WO2009033011A1 (en) * 2007-09-07 2009-03-12 Children's Hospital Medical Center Use of secretor, lewis and sialyl antigen levels as predictors for disease
US20090203538A1 (en) * 2006-07-10 2009-08-13 Institute For Antibodies Co., Ltd. Method of classifying antibody, method of identifying antigen, method of obtaining antibody or antibody set, method of constructing antibody panel and antibody or antibody set and use of the same
US20110311517A1 (en) * 2009-02-10 2011-12-22 Shenogen Pharma Group, Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
US20120195905A1 (en) * 2008-09-19 2012-08-02 Medlmmune, Llc Targeted binding agents directed to dll4 and uses thereof 524
US20130209481A1 (en) * 2010-07-22 2013-08-15 The Regents Of The University Of California Anti-Tumor Antigen Antibodies and Methods of Use

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA128362A (en) 1910-07-25 1910-09-27 Victor Herbert Gregory Furnace for drawing glass
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3668186D1 (en) 1985-04-01 1990-02-15 Celltech Ltd TRANSFORMED MYELOMA CELL LINE AND METHOD USING THE SAME FOR EXPRESSING A GENE ENCODING AN EUKARYONTIC POLYPEPTIDE.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
KR900005995A (en) 1988-10-31 1990-05-07 우메모또 요시마사 Modified Interleukin-2 and Method of Making the Same
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
ATE145428T1 (en) 1990-12-14 1996-12-15 Cell Genesys Inc CHIMERIC CHAINS FOR TRANSDUCTION OF RECEPTOR-CONNECTED SIGNALING PATHWAYS
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
PT1696031E (en) 1991-12-02 2010-06-25 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JPH0630786A (en) * 1992-07-14 1994-02-08 Kyowa Hakko Kogyo Co Ltd Bispecific antobidy
WO1995002420A2 (en) 1993-07-15 1995-01-26 Cancer Research Campaign Technology Ltd. Prodrugs of protein tyrosine kinase inhibitors
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
JPH09506262A (en) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション Method for producing specific antibody
US5925376C1 (en) 1994-01-10 2001-03-20 Madalene C Y Heng Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds
PT744958E (en) 1994-01-31 2003-11-28 Univ Boston BANKS OF POLYCLONE ANTIBODIES
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
HUT76369A (en) 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5911995A (en) 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
ATE331438T1 (en) 1995-01-17 2006-07-15 Brigham & Womens Hospital RECEPTOR-SPECIFIC TRANSEPITHELEAL TRANSPORT OF IMMUNOGENS
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
GB9515975D0 (en) 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US6127366A (en) 1995-11-22 2000-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EE03484B1 (en) 1995-12-08 2001-08-15 Janssen Pharmaceutica N.V. Farnesyl Protein Transferase Inhibitory (5-Imidazolyl) Methyl-2-Quinolinone Derivatives and their Use
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US5958769A (en) 1996-01-18 1999-09-28 Fred Hutchinson Cancer Research Center Compositions and methods for mediating cell cycle progression
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
AU703203B2 (en) 1996-01-30 1999-03-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU704087B2 (en) 1996-01-30 1999-04-15 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ATE279947T1 (en) 1996-03-18 2004-11-15 Univ Texas IMMUNOGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-LIFE TIMES
ATE267610T1 (en) 1996-03-20 2004-06-15 Immunomedics Inc GLYCOSYLATED IGG ANTIBODIES
US6080870A (en) 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5891889A (en) 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6300501B1 (en) 1996-05-22 2001-10-09 Warner-Lambert Company Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
US5648239A (en) 1996-06-21 1997-07-15 Incyte Pharmaceuticals, Inc. Human camp-dependent protein kinase inhibitor homolog
AU2710597A (en) 1996-06-27 1998-01-14 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
NZ334613A (en) 1996-08-12 2002-02-01 Welfide Corp Pharmaceutical agents comprising Rho kinase inhibitor
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
US6040305A (en) 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5945429A (en) 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6013662A (en) 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
US6093737A (en) 1996-12-30 2000-07-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5939439A (en) 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0975603A1 (en) 1997-01-29 2000-02-02 Zeneca Limited Inhibitors of farnesyl protein transferase
ZA981080B (en) 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
WO1998037417A1 (en) 1997-02-20 1998-08-27 The Regents Of The University Of California Plasmon resonant particles, methods and apparatus
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6225322B1 (en) 1997-06-17 2001-05-01 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6159984A (en) 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
US6051582A (en) 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
EA002525B1 (en) 1997-08-15 2002-06-27 Сефалон Инк. Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
US6103723A (en) 1997-10-17 2000-08-15 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6342765B1 (en) 1997-10-22 2002-01-29 Astrazeneca Uk Limited Imidazole derivatives and their use as farnesyl protein transferase inhibitors
AU9452998A (en) 1997-10-22 1999-05-10 Zeneca Limited Imidazole derivatives and their use as farnesyl protein transferase inhibit ors
US6124465A (en) 1997-11-25 2000-09-26 Rhone-Poulenc S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
US6268363B1 (en) 1997-11-28 2001-07-31 Lg Chemical Ltd. Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
US6054466A (en) 1997-12-04 2000-04-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6335156B1 (en) 1997-12-18 2002-01-01 The Johns Hopkins University School Of Medicine 14-3-3σ arrests the cell cycle
DE69904302T2 (en) 1998-02-02 2003-08-14 Lg Chemical Ltd., Seoul/Soul FARNESYL TRANSFERASE INHIBITORS WITH PIPERID STRUCTURE AND METHOD FOR THE PRODUCTION THEREOF
NZ507165A (en) 1998-04-27 2003-06-30 Warner Lambert Co Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
US6034053A (en) 1998-07-13 2000-03-07 Wayne Hughes Institute EGF-isoflavone conjugates for the prevention of restenosis
US6372747B1 (en) 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
US6362188B1 (en) 1998-12-18 2002-03-26 Schering Corporation Farnesyl protein transferase inhibitors
FR2787327B1 (en) 1998-12-21 2003-01-17 Aventis Pharma Sa COMPOSITIONS CONTAINING FARNESYL TRANSFERASE INHIBITORS
US6432959B1 (en) 1998-12-23 2002-08-13 Schering Corporation Inhibitors of farnesyl-protein transferase
DK1140938T3 (en) 1999-01-11 2003-12-22 Univ Princeton High affinity inhibitors for target validation and their applications
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6143766A (en) 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
US6458935B1 (en) 1999-06-23 2002-10-01 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
US6403581B1 (en) 2000-01-19 2002-06-11 American Cyanamid Company Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives
EP1490494A1 (en) 2002-04-01 2004-12-29 Walter Reed Army Institute of Research Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
MXPA06014065A (en) 2004-06-01 2007-01-31 Genentech Inc Antibody drug conjugates and methods.
ES2579805T3 (en) 2004-09-23 2016-08-16 Genentech, Inc. Antibodies and conjugates engineered with cysteine
SI1912671T1 (en) 2005-07-18 2018-01-31 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
ES2534282T3 (en) 2006-06-29 2015-04-21 Dsm Ip Assets B.V. A method to achieve improved polypeptide expression
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
WO2010009124A2 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
CA2867700A1 (en) * 2012-03-23 2013-09-26 Memorial Sloan-Kettering Cancer Center Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
AU2014217561B2 (en) * 2013-02-13 2018-11-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-TNF-alpha antibodies and uses thereof
WO2015053871A2 (en) * 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
GB201515094D0 (en) * 2015-08-25 2015-10-07 Univ Nottingham Sialyl-di-lewis a as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto
CN111630069B (en) * 2017-10-13 2024-05-31 勃林格殷格翰国际有限公司 Human antibodies against Thomsen-nouvelle (Tn) antigen
WO2020081988A1 (en) * 2018-10-19 2020-04-23 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptor targeting sialyl lewis a and uses thereof
EP4314077A1 (en) * 2021-03-26 2024-02-07 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039027A2 (en) * 1997-03-05 1998-09-11 John Wayne Cancer Institute Sialyl lewis antigens as targets for immunotherapy
US20050003469A1 (en) * 1998-12-02 2005-01-06 Applied Molecular Evolution, Inc. Tumor specific human monoclonal antibodies and methods of use
US20090203538A1 (en) * 2006-07-10 2009-08-13 Institute For Antibodies Co., Ltd. Method of classifying antibody, method of identifying antigen, method of obtaining antibody or antibody set, method of constructing antibody panel and antibody or antibody set and use of the same
WO2009033011A1 (en) * 2007-09-07 2009-03-12 Children's Hospital Medical Center Use of secretor, lewis and sialyl antigen levels as predictors for disease
US20120195905A1 (en) * 2008-09-19 2012-08-02 Medlmmune, Llc Targeted binding agents directed to dll4 and uses thereof 524
US20110311517A1 (en) * 2009-02-10 2011-12-22 Shenogen Pharma Group, Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
US20130209481A1 (en) * 2010-07-22 2013-08-15 The Regents Of The University Of California Anti-Tumor Antigen Antibodies and Methods of Use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK Database accession no. PMID: 7693035 *
PRITSCH, O ET AL.: "V Gene Usage By Seven Hybrids Derived From CD 5+ B- Cell Chronic Lymphocytic Leukemia And Displaying Autoantibody Activity.", BLOOD, vol. 82, no. 10, 15 November 1993 (1993-11-15), pages 3103 - 3112, XP055320357 *
SOUZA, TA ET AL.: "Peripheral B Cells Latently Infected With Epstein-Barr Virus Display Molecular Hallmarks Of Classical Antigen-Selected Memory B Cells.", PROC NATL ACAD SCI U S A., vol. 102, no. 50, 13 December 2005 (2005-12-13), pages 18093 - 18098, XP055320355 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137695B (en) * 2015-08-25 2022-03-29 斯坎塞尔有限公司 Sialylated diluisia a expressed on glycoproteins other than glycolipids as a functional cancer target and antibodies thereto

Also Published As

Publication number Publication date
RS62189B1 (en) 2021-08-31
JP2024050966A (en) 2024-04-10
US20150056134A1 (en) 2015-02-26
JP2025116141A (en) 2025-08-07
JP7161397B2 (en) 2022-10-26
HRP20211129T1 (en) 2021-10-15
WO2015053871A2 (en) 2015-04-16
RU2016111015A3 (en) 2018-03-30
PT3041507T (en) 2021-07-26
KR20160054501A (en) 2016-05-16
LT3041507T (en) 2021-08-25
EP3906945A3 (en) 2022-03-16
HK1226295A1 (en) 2017-09-29
KR20220025183A (en) 2022-03-03
SI3041507T1 (en) 2021-11-30
PL3041507T3 (en) 2021-11-15
NZ717428A (en) 2020-09-25
CA3090644A1 (en) 2015-04-16
RU2699289C2 (en) 2019-09-04
JP7635329B2 (en) 2025-02-25
CN112695039A (en) 2021-04-23
AU2020201225B2 (en) 2022-05-05
CA2922478A1 (en) 2015-04-16
JP7299405B2 (en) 2023-06-27
EP3041507A4 (en) 2017-07-12
US9475874B2 (en) 2016-10-25
NZ756328A (en) 2020-09-25
AU2014332442B2 (en) 2019-12-19
AU2022209226A1 (en) 2022-08-18
IL244297A0 (en) 2016-04-21
US20200247900A1 (en) 2020-08-06
WO2015053871A4 (en) 2015-07-30
CY1124435T1 (en) 2022-07-22
CA2922478C (en) 2020-09-29
KR20200085940A (en) 2020-07-15
EP3041507B1 (en) 2021-06-30
RU2016111015A (en) 2017-10-03
RU2019125161A (en) 2019-09-03
KR102362630B1 (en) 2022-02-15
AU2020201225A1 (en) 2020-03-12
IL276819A (en) 2020-10-29
CA3090644C (en) 2023-02-07
US20230365707A1 (en) 2023-11-16
KR20210079426A (en) 2021-06-29
IL244297B (en) 2020-09-30
EP3906945A2 (en) 2021-11-10
AU2022209226B2 (en) 2025-08-21
WO2015053871A8 (en) 2016-03-31
US20170015756A1 (en) 2017-01-19
CN112695039B (en) 2025-07-29
EP3041507A2 (en) 2016-07-13
KR102313341B1 (en) 2021-10-18
CN105764526A (en) 2016-07-13
JP7846285B2 (en) 2026-04-14
JP2021151263A (en) 2021-09-30
SMT202100427T1 (en) 2021-09-14
KR102553717B1 (en) 2023-07-11
BR112016004133A2 (en) 2017-10-24
DK3041507T3 (en) 2021-07-26
ZA201601354B (en) 2020-08-26
JP2016534735A (en) 2016-11-10
JP2023165831A (en) 2023-11-17
JP6626445B2 (en) 2019-12-25
AU2025223771A1 (en) 2025-09-18
HUE056325T2 (en) 2022-02-28
ES2880709T3 (en) 2021-11-25
JP2023026538A (en) 2023-02-24
JP2019047821A (en) 2019-03-28
CN105764526B (en) 2020-12-15

Similar Documents

Publication Publication Date Title
WO2015053871A8 (en) NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
WO2015187811A3 (en) Human monoclonal antibodies to ganglioside gd2
WO2017181031A3 (en) Anti-pacap antibodies and uses thereof
CY1124515T1 (en) ANTI-CGRP COMPOSITIONS AND USES THEREOF
SA519402358B1 (en) Anti-ccr7 antibody drug conjugates
WO2013043933A3 (en) Cd27l antigen binding proteins
WO2018026819A3 (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
MX2023010178A (en) Anti-cd70 antibody drug conjugates.
MY182444A (en) Igf-1r antibody and its use as addressing vehicle for the treatment of cancer
CO6612264A2 (en) Therapeutic proteins of the binding to dll 4
NZ702304A (en) Anti-pcsk9 antibodies and use thereof
BR112015023418A8 (en) anti fgfr2 and fgfr4 antibodies conjugated to the drug, their use and their preparation process, nucleic acid, vector, host cell and diagnostic reagent
WO2009085216A3 (en) Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
WO2015200828A8 (en) Conjugates for immunotherapy
EP4282434A3 (en) Antibodies, uses thereof and conjugates thereof
WO2014057436A3 (en) Anticancer conjugate
PE20071055A1 (en) ANTI MN ANTIBODIES
WO2014007982A3 (en) C-terminal and central epitope a-beta antibodies
WO2019066435A3 (en) Anti-bcma antibody having high affinity for bcma and pharmaceutical composition for treatment of cancer, comprising same
BR112014029089A2 (en) antibody or antigen binding fragment thereof; polynucleotide encoding; compound; pharmaceutical composition / formulation; kit; use; in vitro method for reducing or inhibiting tg2 enzyme activity
WO2019100052A3 (en) Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2011119888A3 (en) N-cadherin: target for cancer diagnosis and therapy
MX2018011039A (en) Podocalyxin and tra-related antibody, methods of preparation and uses as an anti-cancer therapeutic agent.
WO2015191610A3 (en) Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14852746

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2922478

Country of ref document: CA

Ref document number: 2016539019

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 122020012421

Country of ref document: BR

Ref document number: 244297

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016004133

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2014852746

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014852746

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20167007644

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016111015

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014332442

Country of ref document: AU

Date of ref document: 20140826

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14852746

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112016004133

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160225

WWW Wipo information: withdrawn in national office

Ref document number: 717428

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 276819

Country of ref document: IL